HLS Therapeutics Inc.

TSX:HLS.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$3.76 -2.51%

-$0.11 today

Market cap
$116.32M
Beta
0.85
P/E (TTM)
-9.6
EPS (TTM)
-$0.33
52W Low $0.00High $5.77

Volume 0.04M

Average 0.01M

HLS.TO Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

HLS Therapeutics Inc.TSX: HLS.TO

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents falls 30.4% from a year ago

Cash & equivalents stood at $12.33M at the end of Q1 FY2026, down 30.4% from a year earlier and up 5.4% from the prior quarter. Over 3 fiscal years it compounded at -17.3% a year.

Context

  • Cash & equivalents amounted to 9.4% of total assets at the end of Q1 FY2026, down 2.1 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -30.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$12.33M+5.4% QoQ
Last fiscal yearDec 2025
$11.7M-33.0% YoY
Year agoMar 2025
$17.73M-30.4% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-30.4%——
1 year-33.0%——
3-year CAGR-17.3%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
11.7M USD
Year-over-year change
-33.0%
4-year CAGR
-13.8%

Cash & Equivalents vs competitors

How HLS.TO compares with its peers on the latest reported figures

  • HLS.TO's Mar 2026 cash & equivalents of $12.33M is the 6th highest of the 7 companies compared; the peer median is $119.19M.
  • Its year-over-year change of -30.4% is the lowest of 7, against a peer median of +35.0%.
  • Cash & equivalents amounts to 9.4% of total assets for HLS.TO, versus a peer median of 17.8%.
HLS.TO Competitors Peer median
Cash & Equivalents for HLS.TO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NERVMinerva Neurosciences, Inc.Jun 2026$24.65B +161575.2%+31.6%25.9%
BHCBausch Health Companies Inc.Jun 2026$1.83B +5.7%+32.9%7.4%
AMRXAmneal Pharmaceuticals, Inc.Jun 2026$127.64M +57.2%+128.7%3.4%
AQSTAquestive Therapeutics, Inc.Mar 2026$110.73M +61.3%+64.4%78.5%
ETONEton Pharmaceuticals, Inc.Mar 2026$19.66M +12.9%+16.7%20.1%
HLS.TOHLS Therapeutics Inc.Mar 2026$12.33M -30.4%-17.3%9.4%
CPIXCumberland Pharmaceuticals Inc.Mar 2026$11.01M -27.1%-16.6%15.5%
Peer median (excluding HLS.TO) $119.19M+35.0%+32.2%17.8%

Competitors are the stored peer set for HLS.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents21.18M20.72M21.95M17.46M11.7M
Short-term Investments00000
Net Receivables11.51M11.19M10.69M7.53M7.85M
Inventory8.93M8.9M9.53M9.06M8.12M
Other Current Assets1.74M1.43M2K11.37M
Total Current Assets43.75M44.37M44.1M35.4M29.04M
Property, Plant & Equipment (Net)1.57M1.13M965K997K1.34M
Goodwill00000
Intangible Assets229.18M195.02M162.34M122.12M105.43M
Long-term Investments00000
Tax Assets690K465K1.04M857K1.14M
Other Non-current Assets714K668K1.66M528K327.41K
Total Non-current Assets232.15M197.28M164.97M124.5M108.24M
Total Assets275.91M241.65M209.06M159.9M137.28M
Account Payables9.32M11.59M14.11M8.71M10.42M
Short-term Debt12M13.06M4.69M4.83M4.33M
Tax Payables97K0281K152K0
Deferred Revenue4.85M0000
Other Current Liabilities901K6.02M7.14M8.4M10.43M
Total Current Liabilities27.67M31.19M26.69M22.55M26.07M
Long-term Debt84.13M83.28M82.05M60.74M44.37M
Deferred Tax Liabilities653K566K442K4.07M3.05M
Deferred Revenue (Non-current)00000
Other Non-current Liabilities2.54M817K1.77M778K1.67M
Total Non-current Liabilities87.5M85.14M84.68M66.02M49.65M
Total Liabilities115.17M116.33M111.36M88.56M75.72M
Common Stock265.92M265.21M262.13M260.6M255.87M
Retained Earnings(119.86M)(148.45M)(175.46M)(194.18M)(203.78M)
Accumulated OCI2.96M(5.26M)(2.84M)(10.21M)(6.67M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity160.74M125.32M97.7M71.34M61.56M
Total Debt97.57M97.35M87.62M66.45M49.73M
Net Debt76.39M76.62M65.67M48.99M38.03M

HLS Therapeutics Inc.

TSX:HLS.TO

Intrinsic Alpha fair value

Locked

Current Price

$3.76

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.